Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Psoriasis REPLY

被引：0
|
作者：
Papp, Kim A. [1 ]
机构：
[1] Prob Med Res, Waterloo, ON, Canada
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2012年 / 367卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：275 / 275
页数：1
相关论文
共 50 条
  • [41] Authors' Reply to Wang et al., "Comment on 'Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial'"
    Okubo, Yukari
    Kobayashi, Satomi
    Murakami, Masamoto
    Sano, Shigetoshi
    Kikuta, Natsuko
    Ouchi, Yoshiumi
    Terui, Tadashi
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (06) : 1025 - 1027
  • [42] Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis
    Genovese, Mark C.
    Mease, Philip J.
    Greenwald, Maria
    Ritchlin, Christopher T.
    Beaulieu, Andre
    Deodhar, Atul A.
    Newmark, Richard
    Feng, JingYuan
    Erondu, Ngozi
    Nirula, Ajay
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [43] Clinical Response in Subjects with Psoriatic Arthritis Following One Year of Treatment with Brodalumab, an Anti-Interleukin-17 Receptor Antibody
    Genovese, Mark C.
    Mease, Philip
    Greenwald, Maria W.
    Ritchlin, Christopher T.
    Beaulieu, A.
    Deodhar, Atul A.
    Newmark, Richard
    Feng, JingYuan
    Erondu, Ngozi
    Nirula, Ajay
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S687 - S687
  • [44] Interleukin 12/23 monoclonal antibody in the treatment of psoriasis
    Heller, Marissa
    JOURNAL OF DRUGS IN DERMATOLOGY, 2008, 7 (04) : 417 - 417
  • [45] Safety profile of ixekizumab, an anti-IL-17 monoclonal antibody, in chronic plaque psoriasis patients after at least 1 year of open label treatment
    Gordon, Kenneth
    Leonardi, Craig
    Braun, Daniel
    Cameron, Gregory
    Erickson, Janelle
    Lebwohl, Mark
    Heffernan, Michael
    Banerjee, Subhashis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB184 - AB184
  • [46] Impact of anti-interleukin-17 treatment on cutaneous and genital human papillomavirus infection
    Brunet-Possenti, F.
    Charpentier, C.
    Collin, G.
    Descamps, D.
    Descamps, V.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (05) : 1179 - 1180
  • [47] Intramatricial injection of anti-interleukin-17A antibody for six patients with nail psoriasis
    He, F.
    Long, F. Y.
    Zhang, Z. Q.
    Xia, R. Y.
    Lu, Y.
    Yin, Z. Q.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2022, 47 (02) : 432 - 433
  • [48] Is an anti-interleukin-17 receptor able to do the job when an anti-interleukin-12/23 has failed?
    Montaudie, H.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (02) : 255 - 256
  • [49] Effect of Anti-interleukin-17 Treatment on Haemoglobin A1c Levels
    Schwarz, Christopher Willy
    Loft, Nikolai Dyrberg
    Zachariae, Claus
    Skov, Lone
    ACTA DERMATO-VENEREOLOGICA, 2020, 100 : 1 - 2
  • [50] Efficacy and safety of ixekizumab, an interleukin-17A monoclonal antibody, in real-world patients with psoriasis: 12-week results from a Canadian multicenter retrospective study
    Georgakopoulos, Jorge R.
    Phung, Michelle
    Ighani, Arvin
    Yeung, Jensen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB120 - AB120
12345